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Abstract 
Biodistribution and infarct accumulation of different liposome preparations in rabbits with experimental myocardial infarction have 
been investigated. The influence of such parameters as liposome size, and presence or absence of poly(ethylene glycol) (PEG) and 
infarct-specific antimyosin antibody (AM) on liposome behavior in vivo was studied. All three variables were shown to affect liposome 
biodistribution, liposome size being the least significant variable. Statistical analysis of the data obtained demonstrated that of all 
variables, PEG coating expresses the strongest influence on the liposome blood clearance, significantly (P = 0.0001) increasing the mean 
level of blood radioactivity under all circumstances. Infarct accumulation depended upon the presence of both PEG (P = 0.0013) and AM 
(P = 0.005). The infarct-to-normal r tio was affected by the presence of AM (P = 0.0002), but the extent of the effect depended also on 
the presence of PEG (P = 0.01). Two differing mechanisms can be seen in infarct accumulation of PEG-liposomes (slow accumulation 
via the impaired filtration) and AM-liposomes (specific binding of immunoliposomes with the exposed antigen). Both mechanisms are 
supplementary in case of liposomes carrying PEG and AM at the same time. An optimization strategy is suggested for using liposomes as 
carriers for diagnostic (a high target-to-nontarget ratio is required) and therapeutic (a high absolute accumulation i the target is required) 
agents. 
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1. Introduction 
The targeting of pharmaceuticals to the heart is aimed at 
two main objectives: diagnostic imaging and the delivery 
of therapeutics to the damaged myocardium. Liposomes 
have been shown to serve as convenient carriers for both 
diagnostic and therapeutic pharmaceuticals. Spontaneous 
accumulation of positively charged liposomes in the re- 
gions of experimental myocardial infarction was described 
by Caride in 1977 [1]. Further experiments [2-4] demon- 
strated that liposome accumulation i ischemic tissues is a 
general phenomenon and might be explained by impaired 
filtration in these areas, resulting in trapping of liposomes 
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within the ischemic zones [5]. This observation led to the 
conclusion that drug-loaded liposomes can be used for 
'passive' drug delivery into the ischemic tissues, particu- 
larly into the infarcted myocardium [6,7]. Thus, liposomes 
loaded with a thrombolytic enzyme, streptokinase, were 
able to accelerate thrombolysis and reperfusion i  a canine 
model of myocardial infarction [8]. Liposomes with super- 
oxide dismutase were reported to be more effective in 
preventing ischemic and reperfusion injuries in different 
tissues, including myocardium, compared to the native 
enzyme [9,10]. Furthermore, it was shown that liposomes 
loaded with sodium or calcium ions have demonstrated 
significant influence on the electrical activity of cultured 
heart cells from chicken embryos [l 1]. Similarly, lipo- 
somes with entrapped ATP were shown to normalize 
ischemic onditions in some tissues [12]. 
To improve the efficiency of liposomal drug delivery 
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into the ischemic myocardium utilisation of antibody- 
mediated liposome targeting was proposed. Antimyosin 
antibody [13,14] has been used for "active' targeting of 
liposomes to infarcted myocardium [15]. This targeting 
phenomenon is based on the observation that normal my- 
ocardial cells with intact membranes do not permit extra- 
cellular macromolecules, such as antimyosin antibody, to 
traverse the cell membrane. However, necrotic ardiomy- 
ocytes with disrupted membranes can no longer prevent 
the antibody from interacting with myosin [16]. This forms 
a basis for targeted elivery of pharmaceuticals into the 
affected myocardium [17]. Antibody to canine cardiac 
myosin covalently coupled to liposomes has been success- 
fully used for targeting of the experimental myocardial 
infarction in dogs [ 15]. Incorporation of radioactivity within 
liposomes also allowed for visualization of the necrotic 
myocardium [15]. 
However, 'passive' liposome targeting or 'active' tar- 
geting with immunoliposomes can not provide high enough 
accumulation of the targeting agent in the areas with 
limited blood supply (such as an infarct zone) due to fast 
sequestering of liposomes by the reticuloendothelial sys- 
tem (RES), resulting in insufficient contact ime with the 
target. Some in vivo properties of liposomes, such as 
circulation time, can be improved by grafting their surface 
with certain flexible polymers [18-20]. One of the most 
promising approaches for increasing liposome circulation 
time is coating them with poly(ethylene glycol), or PEG. 
PEG decreases the rate of opsonization of liposomes and 
therefore their recognition by liver cells, which signifi- 
cantly increases liposome circulation time in the blood 
[21,22]. Moreover, long-circulating polymer-coated lipo- 
somes can be made target-specific' by co-incorporation f
a specific antibody on the liposome surface, as described 
earlier [23]. In that study, antimyosin-modified PEG-lipo- 
somes had the abilities to recognize and bind the target, as 
well as circulate long enough to provide high target accu- 
mulation. The next step in this endeavor is to optimize 
liposome properties for the delivery of diagnostic and 
therapeutic agents into the damaged myocardium. For 
diagnostic purposes maximum target-to-nontarget ratio is 
essential; whereas, for therapeutic purposes the maximum 
absolute dose delivery of the liposomal contents into the 
affected tissue is more important. However, with highly 
toxic pharmaceuticals, high background is undesirable and 
low non-specific accumulation could be required. With 
these aims in mind, in vivo properties and biodistribution 
of PEG and/or antimyosin antibody-coated liposomes of 
different sizes were investigated in rabbits with experimen- 
tal myocardial infarction. 
We report here that in the rabbit myocardial infarct 
model, the size of the liposomes has limited influence on 
their in vivo behavior and accumulation atthe target organ. 
The presence of antibody and/or PEG on the liposome 
surface is more critical resulting in differences which may 
influence whether its use should be in diagnosis or therapy. 
2. Materials and methods 
2.1. Materials 
Diethylenetriaminepentaacetic acid (DTPA) cyclic an- 
hydride, monomethoxy poly(ethylene glycol) succinimidyl 
succinate (PEG-OSu), M r approx. 5000, l-ethyl 3-(3-di- 
methylaminopropyl) carbodiimide (EDC), octyl glucoside 
(OG), and cholesterol were purchased from Sigma Co. (St. 
Louis, MO). Dioleoylphosphatidylethanolamine (PE), egg 
yolk phosphatidyicholine (PC), and N-glutaryiphospha- 
tidylethanolamine (NGPE) were obtained from Avanti Po- 
lar Lipids (Alabaster, AL). N-Hydroxysulfosuccinimide 
(HSSI) was from Pierce (Rockford, IL). Carrier-free i l l  In 
as InCl3 was obtained from Amersham (Arlington Heights, 
IL). Mouse monoclonal antibody RI IDl0 or 2G4-2D7 
specific for cardiac myosin heavy chains was prepared as 
described [ 16]. 
2.2. Methods 
Synthesis of PEG-PE. The synthesis of PEG-PE was 
performed as described in [21]. Briefly, an aliquot of 
PEG-OSu was added to a solution of PE in chloroform, 
followed by addition of triethylamine (PEG-OSu/PE/tri- 
ethylamine = 3:1:3.5, mol/mol). The reaction mixture is 
incubated overnight at room temperature and the chloro- 
form is evaporated with a stream of nitrogen gas. The 
reaction mixture is than redissolved in 0.145 M NaCI. 
Unreacted PEG-OSu is rapidly hydrolyzed in the aqueous 
media. The resulting mixture in saline is applied to a 
Bio-Gei AI.5m column equilibrated with saline. Peak frac- 
tions containing PEG-PE micelles eluted in the void vol- 
ume are pooled, dialyzed against water and lyophilized. 
Preparation of antibodies and their fragments. Mono- 
cional antibodies were purified according to the standard 
method from corresponding murine ascites by ammonium 
sulfate precipitation, DEAE-ceilulose anion exchange 
chromatography, and chromatofocusing over a pH gradient 
of 7.0 to 5.0 [16]. Antibody preparations were charac- 
terized by gel electrophoresis and HPLC. Fab fragments 
were used instead of whole antibodies in order to decrease 
Fc-mediated uptake of liposome-whole antibody conju- 
gates by cells of the reticuloendothelial system (RES). The 
digestion of IgG and Fab purification was performed as 
follows: (a) 0.5 mi of the 50% slurry of immobilized 
papain (Pierce) were washed two times with 4 ml of 
digestion buffer (42 mg of cysteine/12 ml of phosphate 
buffer (pH 7.0)) for equilibration, and then suspended in 
0.5 ml of the same buffer; (b) 0.5 ml of IgG sample 
(10-20 mg protein/ml) were diluted with 0.5 ml of the 
digestion buffer and added to the tube with immobilized 
papain suspension; (c) incubation proceeded for overnight 
depending at 37°C with intensive stirring; digestion degree 
was monitored with HPLC; (d) digested Fab and Fc frag- 
ments, and non-digested IgG were separated from papain 
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gel; (e) column with 5 ml of protein A-Sepharose (Phar- 
macia) was equlibrated with phosphate-buffered saline 
(PBS) (pH 8.0), and digested IgG sample was applied; (f) 
column was washed with PBS, Fab fragment was collected 
(purity was checked by HPLC); (g) Fc fragment was 
washed away with 0.1 M glycine (pH 3.0) to regenerate 
the column. 
Antibody modification. For the incorporation into the 
liposomal membrane, antimyosin antibody Fab was ini- 
tially modified with the hydrophobic anchor, NGPE, as 
described in [24]. Briefly, 0.3 mg of NGPE were dried 
with argon from chloroform solution and then solubilized 
with 0.5 ml of 0.016 M OG in 50 mM Mes. The solution 
was supplemented with 12 mg EDC and 15 mg of HSSI. 
The mixture was incubated for 5 min and then added to the 
solution of 2 mg of Fab in 0.1 M Hepes (pH 7.6). pH was 
adjusted to 8.0 with 1 M NaOH, and the mixture was 
incubated overnight at 4°C. The modified antibody was 
purified by dialysis against HBS. 
Preparation of liposomes. Liposomes were prepared by 
the detergent (OG) dialysis from the mixture of PC and 
cholesterol (7:3 molar ratio). 6 mol% of PEG-PE and 1 
mol% of DTPA-SA were added to the lipid mixture, which 
was then argon-dried, vacuumed, solubilized w~th OG in 
Hepes-buffered saline (HBS) (pH 7.4) (final total lipid 
concentration may vary from 5 to 20 mg/ml), and dia- 
lyzed overnight against HBS at 4°C. When necessary, 0.01 
mol% of NGPE-antimyosin Fab was added to OG-solubi- 
lized lipid mixture to prepare targeted liposomes. Modifi- 
cation with NGPE normally allows the binding of several 
hundred protein molecules per single 250 nm liposome 
[24]. As was shown with 125I-labeled antibody, in our 
particular case the efficacy of protein binding varied be- 
tween 65 and 75% and did not depend on the presence of 
PEG-PE in the lipid mixture. The unbound antibody was 
separated on a Bio-Gel A15m column as in [23]. Lipo- 
somes obtained were sized by passing through the polycar- 
bonate filters with pore size of 0.6, 0.4, and 0.2 /zm 
(Nuclepore). Liposomes of two sizes were prepared: 120- 
150 nm (small liposomes, SL) and 350-400 nm (large 
liposomes, LL). Actual size and size distribution of lipo- 
somes were determined with Coulter N4 MD Submicron 
Particle Size Analyzer (Coulter Electronics). 
For biodistribution studies, liposomes were radioac- 
tively labeled with H1 In via liposome-incorporated am- 
phiphilic chelating agent diethylenetriaminepentaacetic 
acid-stearylamine (DTPA-SA). DTPA-SA was synthesized 
according to recommendations of [25] with some changes. 
Briefly, 1.55 g of SA and 2.5 g of DTPA cyclic anhydride 
were mixed with 250 ml of dry chloroform. The mixture 
was refluxed for 1 h, the top outlet of the system being 
coated with foil. Then, 3 ml of triethylamine were added, 
and the mixture was refluxed for an additional 48 h. 
Chloroform was evaporated on the rotor evaporator, it's 
traces were removed by incubating the flask in the water 
bath at 50°C. 100 ml of 0.1 M HC1 were added to the dry 
product, and the mixture was stirred with heating at 80°C 
for 10 min and stored overnight at room temperature. The 
precipitate was separated by centrifugation, washed three 
times with 100 ml of 0.1 M HC1 with stirring, and then 
lyophilized. The lyophilized product was washed twice 
with 100 ml of methanol, and then recrystallized twice 
from boiling methanol and dried. 
DTPA-SA loading with 111In was performed after its 
incorporation i to liposomes via the transchelation mecha- 
nism. For this purpose, the liposome suspension (normally, 
2 ml) was supplemented with 30 /zl of 1.0 M citrate and 
incubated for 1 h with required quantity of citrate complex 
of ill In at room temperature, and then dialyzed overnight 
against HBS at 4°C to remove free label. 
Determination of antibody-liposome immunoreactivity 
by direct binding of radiolabeled antibody-liposome and 
antibody-liposome-polymer conjugates. Microtiter plates 
were coated with 50 /zl of 10-50 /zg/ml of dog cardiac 
myosin and incubated at 4°C for 12-18 h. The antigen 
solution was removed and the wells were filled with 1% 
horse serum in 0.15 M phosphate-buffered saline (pH 7.4) 
to saturate the remaining non-specific binding surfaces of 
the microtiter wells. The solution was removed after a 4 h 
incubation at room temperature and the wells were washed 
extensively with standard washing solution. To the anti- 
gen-coated wells prepared as described above, serial dilu- 
tions of l~lln-labeled antibody-polymer-liposome prepara- 
tion were added. The maximum count used per 50 /zl 
aliquot was 2 • 105 cpm. Half dilutions were made until the 
aliquots contained approximately 10000 cpm per 50 /xl. 
The reaction was allowed to proceed until equilibrium, for 
4 h at room temperature or overnight at 4°C. The wells 
were extensively washed to remove slightly-bound ra- 
dioactivity, cut and counted in a T-scintillation counter for 
1~ 1 In activity. Binding of 1~  In-labeled antibody-polymer- 
liposome conjugates was compared with the binding of 
corresponding antibody directly labeled with lllln via 
DTPA technique. 
Experimental myocardial infarction in rabbits. Rabbits 
(New Zealand White rabbits, 2-3 kg) were anesthetized 
with Ketamin (70-75 mg/kg) and Xylazine (7-7.5 
mg/kg). Right femoral artery cut-down was performed to 
establish a blood pressure line and for arterial blood 
sampling. The right femoral vein was catheterized to allow 
intravenous medication. A tracheostomy was performed, 
and ventilation was instituted through an endotracheal tube 
with a Harvard Rodent Ventilator (model 683). After 
artificial respiration, the anesthesia was switched to 3 ml 
(19.5 mg) pentobarbital infusion per hour. A left thoraco- 
tomy was performed and the anterior descending coronary 
artery was occluded with a silk suture placed through the 
myocardium with an SH-needle. After 40 min, the snare 
was released to allow reperfusion. A radiolabeled liposome 
preparation (2-3 ml in HBS, up to 30 mg of total lipids 
and 200 to 500 /zCi of l~In) was injected intravenously 
within 30 min of reperfusion. Blood samples were taken 
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serially at 1, 3, 5, 10, 20, 30, 45, 60, 90, 120, 150, 180, 
240 and 300 min after injection of liposomes to measure 
blood radioactivity (liposomal clearance). Time within 
which the blood content of the liposome-associated ra- 
dioactivity dropped to 50% of the injected dose was 
designated as t~/2. 5 h after liposome injection, animals 
were killed by an overdose of pentobarbital. The heart was 
excised and cut into 5 mm slices, stained with 2% triph- 
enyl tetrazolium chloride to identify necrotic areas. Each 
slice was further divided into smaller segments for biodis- 
tribution studies following a standard scheme [23]. Sam- 
ples of normal and infarcted myocardium, and other organs 
of interest were dried from excessive blood by blotting on 
absorbant owels and then weighed and counted in a 
gamma-counter. The liposome accumulation i the heart 
was expressed as infarct-to-normal myocardium radioactiv- 
ity ratio. Biodistribution of liposomes was also studied 
following the liposome-associated ra ioactivity accumula- 
tion in nontarget organs (such as liver, spleen, kidneys and 
lung), and expressed as %dose per g of the tissue. 
Statistical treatment of the animal data. The liposomes 
were prepared varying three factors: size (SL and LL), 
PEG coating and antimyosin antibody (AM) coating. Eight 
subgroups of animals were studied, four for each SL and 
LL groups. The four subgroups for each size included 
plain liposomes, PEG(only)-coated liposomes, AM(only)- 
coated liposomes, and PEG-AM(coincorporated) lipo- 
somes. Each subgroup comprised 3-5 rabbits. The contri- 
bution of each of the three experimental factors to the 
infarct-to-normal myocardium radioactivity ratio and the 
liposome accumulation i the liver, spleen, kidney, and 
lung were analyzed with a three-way factorial analysis of 
variance. Each model was reduced to the significant terms 
(P < 0.05), and all effects were estimated. They are pre- 
sented as estimate (+ standard error). Means of the ob- 
served values were used to present the biodistribution data, 
while means of the corresponding ratios were used to 
estimate infarct accumulation (Table 1). 
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Fig. 1. Blood clearance of different liposomes in rabbits with experimen- 
tal myocardial infarction. (A) Small liposomes. 1, SL; 2, AM-SL; 3, 
PEG-AM-SL; 4, PEG-SL. (B) Large liposomes. 1, LL; 2, AM-LL; 3, 
PEG-AM-LL; 4, PEG-LL. 
3. Results 
3.1. Immunoreactiuity 
The modification of antimyosin R11D10 Fab with hy- 
drophobic substituent NGPE, and incorporation of NGPE- 
Fab into the liposomal membrane in this particular case 
decreased antibody immunoreactivity by approximately 15- 
to 20-times. The appropriate binding constant decreased 
from 5.108 for the native Fab to 3. 10 7 for NGPE-Fab, 
and to 2.107 M -] for an individual NGPE-Fab in lipo- 
some. However, as demonstrated arlier, such a decrease 
in immunoreactivity of an individual antibody is at least 
partially compensated by the increase in avidity due to the 
presence of multiple antibody molecules on the liposome 
surface providing specific multipoint attachment of im- 
munoliposome to the target [26]. As a result, the apparent 
constant of immunoliposome binding to the antigen was in 
the range (3-6). 108 M- l  liposomes. 
3.2. Blood clearance 
The patterns of clearance of different liposome prepara- 
tions from the circulation in infarcted rabbits are presented 
in Fig. 1. 
3.3. Biodistribution 
The biodistribution data obtained after 5 h of experi- 
ment were expressed as % of injected dose per gram of 
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tissue. The statistical analysis of the data related to individ- 
ual organs revealed the following (see also Table 1): 
Blood. The blood radioactivity at 5 h depended signifi- 
cantly upon the interaction (combination) of all three 
factors (P  = 0.006). The strongest effect was observed for 
the PEG coating, which significantly (P=0.0001)  in- 
creased the mean level under all circumstances. The esti- 
mated effect was 0.44 (_+ 0.06) for SL without AM coat- 
ing, 0.19 (_+0.06) for AM-SL, 0.32 (+0.06) for LL 
without AM, and 0.31 (_+ 0.06) for AM-LL. 
Infarcted area. In the infarcted myocardium, accumula- 
tion depended significantly upon the presence or absence 
of both the PEG coating (P  = 0.0013) and the antimyosin 
antibody (P = 0.005). Both coatings increased the mean 
infarct accumulation: PEG - 0.10 (___ 0.03), and AM - 0.09 
(_+ 0.03); for all PEG-containing vs. corresponding PEG- 
free, and AM-containing vs. corresponding AM-free sam- 
ples, respectively. Minimum accumulation was observed 
for both SL and LL - 0.02 + 0.01 ; maximum accumulation 
was found for PEG-AM-SL - 0.25 + 0.14. 
Normal myocardium. Normal myocardium was demon- 
strably affected only by the PEG coating (P  = 0.0001). 
The coating was estimated to increase the mean value by 
0.013 (+0.002). 
Infarct-to-normal ratio. The infarct-to-normal r tio was 
demonstrably affected by the presence or absence of an- 
timyosin antibody on the liposome (P = 0.0002). How- 
ever, the extent of the effect depended significantly upon 
the presence or absence of the PEG coating together with 
AM (P = 0.01). In liposomes without any PEG coating, 
the AM coating increased the mean ratio by 21 (___ 4). In 
liposomes with the PEG coating, the AM coating is esti- 
mated to increase the mean ratio by only 5 (+4). This 
effect is not statistically significant (P  = 0.22). Maximum 
value of the infarct-to-normal r tio was achieved for AM- 
SL - 22.70 ± 2.38. The value for AM-LL (29.67) can not 
be considered as reproducible because of large standard 
deviation (23.76). 
Liver. Liver radioactivity accumulation was affected by 
both the PEG and AM coatings. Liposomes with PEG 
coating alone, the AM coating alone, or both had signifi- 
cantly (P  = 0.007, 0.0003, and 0.0005, respectively) lower 
mean liver activity values than liposomes with neither 
coating. The differences can also be noticed between the 
mean values of accumulation of liposomes with either or 
both coatings (see Table 1). 
Spleen. Spleen accumulation was not demonstrably af- 
fected by any of the three factors (size, PEG, AM). 
Kidney. Radioactivity accumulation i the kidney was 
shown to be affected only by the PEG coating (P  = 0.002) 
which was estimated to increase the mean value by 0.028 
( + 0.008). 
Lung. Radioactivity accumulation i  the lung was shown 
to be affected only by the PEG coating (P=0.0003)  
which was estimated to increase the mean value by 0.09 
(+0.02). 
4. Discussion 
Numerous in vitro and in vivo studies already have 
dealt with the interaction of long-circulating liposomes 
with cells and organs [27-29]. These studies have clearly 
documented the dependence of liposome clearance rate 
and the biodistribution pattern on liposome size and the 
presence of the protective substances on the iiposome 
surface. However, attempts to prepare long-circulating im- 
munoliposomes have added one more variable to the sys- 
tem, the targeting moiety (such as a monoclonal antibody). 
At a given phospholipid composition, the properties of the 
long-circulating immunoliposomes would depend on the 
liposome size, and the presence of both, the protective 
substance and antibody on the liposome. Therefore, permu- 
tations of these variables should enable the control of 
liposomal characteristics, such as clearance time, biodistri- 
bution, and target accumulation. This should permit prepa- 
ration of liposomes pecifically designed for targeted e- 
livery of diagnostic agents (where maximum liposome 
accumulation i the target area and minimum accumula- 
tion in normal tissues are required to provide maximum 
target-to-nontarget ratio) and of therapeutic agents (where 
maximum absolute accumulation of drug-loaded liposomes 
in the target is required). 
4.1. Blood clearance characteristics 
Small liposomes. In case of SL, plain liposomes demon- 
strate the fastest clearance. Addition of AM slightly in- 
creases the circulation time probably by reducing the 
unaltered surface of liposomes which determines the lipo- 
some accessibility to opsonons [19,30]. Since we used Fab 
fragment of the antibody, immunoliposome capture via Fc 
fragments did not occur as in case of the whole IgG. 
Grafting of PEG to the liposome surface, as expected 
[21,23], sharply increases liposomai circulation time. Si- 
multaneous incorporation of AM and PEG also signifi- 
cantly increases the circulation time, the blood clearance 
was marginally faster compared to the PEG liposomes. 
This difference in the clearance can be partly explained by 
a more pronounced interaction between AM and plasma 
proteins than between PEG and the same proteins. How- 
ever, significantly longer circulation of PEG-AM-SL as 
compared to AM-SL allows for effective targeting as 
described by us previously [23]. 
Large liposomes. The clearance characteristics of LL 
are similar to SL. The only exclusion is that AM Fab 
incorporation practically does not influence circulation time 
of PEG-LL. This can be explained by size difference 
between SL and LL; the surface area of LL is approxi- 
mately 6 times larger than that of SL, and possible irregu- 
larities in PEG location (such as the hypothetical formation 
of more dense PEG clusters because of polymer-to-poly- 
mer interactions which can result in the appearance of 
polymer-free areas on the liposome surface xposed for the 
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Table 2 
Liposome circulation time 
Liposome Variable tl/2 (min) Comments 
Small plain 10-15 
+ AM (Fab) 15-20 
+PEG > 1000 
+ AM/+ PEG ca. 600 
Large plain ca. 10 
+AM (Fab) ca. 15 
+ PEG > 600 
+ AM/+ PEG 
Very short tj/2 
Slight increase (due to partial surface protection?) 
Significant increase (full surface protection) 
Intermediate increase (interaction with plasma 
proteins is stronger for Fab than for PEG) 
Very short t~/2 
Slight increase; same as for SL 
Significant increase in circulation time, but still less than for PEG-SL. 
No difference between PEG- and PEG-AM-LL: possible irregularities 
in surface PEG distribution (and consecutive opsonization) 
are more probable for LL. 
opsonization) are more probable for PEG-LL than for 
PEG-SL. This is why the circulation time for PEG-LL is 
less than that for PEG-SL, and additional incorporation of 
AM Fab onto the surface of LL does not significantly 
change the clearance. Some alternative xplanations are, 
probably, also possible. 
The circulation time is therefore strongly influenced by 
all three factors studied - liposome size and the presence 
of AM, PEG or both on the liposome surface (see Table 
2). However, size difference seems to be less important 
than surface modification with PEG or AM. 
4.2. Targeting of the infarcted myocardium 
Small liposomes. There is a marginally higher localiza- 
tion of plain SL in the infarcted myocardium as compared 
with remote normal myocardium. Such non-specific local- 
ization of liposomes in the injured myocardium has been 
shown previously [1-5]. Interestingly, both PEG-SL and 
AM-SL accumulate in the necrotic area almost identically 
if the total is expressed in absolute quantities, 0.13 and 
0.14% dose/g, respectively. This indicates two different 
mechanisms for liposomal accumulation. Firstly, the spe- 
cific one, which requires the presence of antibodies on the 
surface of short-circulating liposomes and permits selec- 
tively intense targeting of necrotic myocardium even after 
few passages over the area of interest [15]. Second mecha- 
nism is likely to be a non-specific, which slowly proceeds 
via impaired filtration mechanisn~ in affected tissues with 
leaky vascular endothelium and requires repeated passages 
of liposomes through the target, i.e., prolonged circulation. 
The phenomenon of the accumulation of long-circulating 
liposomes has been reported previously in tumors with 
highly permeable ndothelial ayer [31,32], where the 
necrotic zone (if any) may also suffer from impaired 
drainage still further facilitating liposome accumulation. 
Although absolute accumulation of AM-SL and PEG-SL 
is similar, the infarct-to-normal r tio (or relative targeting) 
is much higher for AM-SL than for PEG-SL; 22.70 + 2.38 
versus 8.05 + 5.03, respectively. The reason for this inter- 
esting phenomenon is that the non-specific accumulation 
of AM-SL in normal tissues is very low (the time of 
AM-SL residence in the blood is too short). On the other 
hand, long-circulating PEG-SL slowly and non-specifically 
accumulate in both infarcted and normal tissues but the 
accumulation i infarcted tissued is comparatively higher 
due to exaggerated vascular permeability. 
The combination of AM and PEG (PEG-AM-SL) on the 
liposome surface adversely affects the target-to-normal 
ratio, which is lower than that of AM-SL due to higher 
non-specific apture of PEG-AM-SL in normal tissue. 
However, in absolute terms (% dose/g) this combination 
provides excellent accumulation (0.25 +0.14) which is 
2-fold higher than for short-circulating AM-SL. The in- 
tense PEG-AM-SL accumulation i the infarcted tissue can 
be explained by both specific and non-specific mecha- 
nisms of accumulation acting synergistically. 
Large liposomes. Although, PEG and AM predomi- 
nantly affected the target accumulation of liposomes, the 
liposome size also influences the targeting to some extent. 
The increase in liposome size reduces their ability for 
non-specific accumulation i  the necrotic tissues. It can 
simultaneously affect the efficacy of AM-LL interaction 
with the target; for example, in the case when due to a 
short contact time with the target, part of fast-clearing 
AM-LL fail to form a sufficient number of Fab-antigen 
bonds to firmly anchor a large liposome to the target. 
Similar to plain SL, no noticeable accumulation ofplain 
LL occurs in the infarction due to brief residence time. The 
accumulation of both AM-LL and PEG-LL is higher. In 
case of LL, absolute accumulation of PEG-LL is even 
slightly better than that of AM-LL (0.14 + 0.04 and 0.09 
___ 0.04% dose/g, respectively). Evidently, for LL pro- 
longed circulation can yield greater absolute accumulation 
through gradual accumulation than short-term specific in- 
teraction, part of which can be non-productive b cause of 
the large liposome size. Comparing these data with that of 
SL, one can hypothesize that to overcome the disadvantage 
of liposome size, at least a minimum critical residence 
time may be required for immunoliposome targeting. 
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Table 3 
Liposome targeting to infarcted myocardium 
Liposome Variable % dose/g Comments 
Small plain 0.02 
+ AM (Fab) 0.14 
+PEG 0.13 
Large 
+AM; +PEG 0.25 
plain 0.02 
+ AM (Fab) 0.09 
+PEG 0.14 
+Ab; +PEG 0.15 
Very low accumulation 
Good and similar. Two mechanisms work: (1) specific binding and (2) 
non-specific accumulation due to impaired filtration. Relative 
targeting (target-to-normal ratio) is much better for AM-SL (22.7) 
than for PEG-SL (8.05), because of low accumulation fAM-SL 
in normal tissues (fast clearance) and high accumulation f PEG-SL 
(slow clearance) 
Absolute accumulation is maximal; 0.25% dose/g: both mechanisms 
work/Relative targeting is intermediate (14) because of high 
non-specific accumulation i  normal tissues. 
Very low accumulation. 
Good and relatively close accumulation. Prolonged circulation might 
be even more effective than short-term specific interaction. Relative 
accumulation for AM-LL is again higher than for PEG-LL because 
of non-specific accumulation f PEG-LL in normal tissue. 
No improvement compared to PEG-LL: limiting step is non-specific 
accumulation i  normal tissues; no room for AM additive ffect. 
In spite of relatively low AM-LL accumulation i farct- 
to-normal ratio remains higher for AM-LL than for PEG-LL 
due to essentially no non-specific uptake of AM-LL in 
normal myocardium (infarct-to-normal ratios, AM-LL 
29.67 4- 23.76 vs PEG-LL 7.38 4- 1.67). 
Co-incorporation of AM and PEG into the same lipo- 
some does not improve absolute accumulation of large 
liposomes. This can be explained by predominant effect of 
non-specific accumulation via impaired filtration mecha- 
nism which may offset the advantage of specific targeting 
in the case of LL. Infarct-to-normal r tio for PEG-AM-LL 
is between that for AM-LL and PEG-LL. Maximum accu- 
mulation of PEG-AM-LL is also less than that of PEG- 
AM-SL. 
The maximum infarct-to-normal ratios could therefore 
be achieved for AM-SL, which makes them attractive for 
the targeted elivery of the agents where the maximum 
difference between the area of interest and normal tissues 
is desired (such as imaging agents). At the same time, for 
the requirement of maximum absolute delivery within the 
target issue, liposomes combining on the surface both a 
protective polymer and an antibody appear to be the 
carders of choice (PEG-AM-SL in our particular case) 
(Table 3). 
4.3. Liposome biodistribution in nontarget organs 
The biodistribution of both SL and LL and their sur- 
face-modified erivatives reconfirms previously known 
characteristics (Table 1). 
Small liposomes. Plain SL and AM-SL are sequestered 
predominantly in the liver and spleen followed by a mod- 
est capture in kidneys and lungs. PEG modification of 
liposomes with or without AM modification, significantly 
decreases liposome accumulation i reticuloendothelial or-
gans, while noticeably increasing it in kidneys and lungs. 
Pulmonary accumulation can be increased 8-fold. 
Large liposomes. The common features of biodistribu- 
tion pattern are preserved for different types of LL. Similar 
to the biodistribution of SL, sequestration f plain LL and 
AM-LL is observed in the liver and spleen. The protective 
effect of PEG modification is less pronounced than for 
small liposomes. LL with both AM and PEG on the 
surface accumulate in the spleen twice as much as SL 
counterpart. Lung accumulation is 3.5-times higher for 
plain LL than for plain SL, and increases further for 
PEG-coated LL. Nonspecific LL distribution in renal tissue 
was same as that for SL. 
From the statistical analysis of the experimental data in 
the present study some important conclusions can be drawn 
with reference to the mechanisms of liposome accumula- 
tion in the target tissues, and optimization of liposome 
properties i suggested for their use as vehicles for various 
pharmaceuticals tailored to clinical demands. 
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